Phase 2 N=31 Memory and Insulin in Early Alzheimer's Disease
Alzheimer's Disease
Primary: fMRI Measure of Hippocampal Activation — 36.4; 41.3 percentage of active voxels
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Rate of Disease Control (Freedom From Disease Progression) — 4 participants
Phase 2 N=29 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
Metastatic Colorectal Cancer
Primary: Response Rate of Lapatinib/Capecitabine. — 4; 1 participants
Phase 2 N=24 Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
Restless Legs Syndrome
Primary: Apparent Total Body Clearance (Cl/f) of Unconjugated Rotigotine 0.5 mg/24 h (2.5 cm^2) — 676.86 L/h (liter per hour)
Phase 2 N=51 Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Tumor Response — 14.3 percentage of participants
Phase 2 N=44 Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
HIV Infections
Primary: Time to Confirmed Virologic Failure — 28; 29 weeks
Phase 2 N=45 Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
Kidney Transplantation
Primary: Calculated Glomerular Filtration Rate (GFR) Using the Modification of Diet in Renal Disease (MDRD) Equation — 67.06; 65.99; 67.05; 64.97 mL/min/1.73 m^2
Phase 2 N=30 Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
Leukemia · Myelodysplastic Syndromes
Primary: Complete and Partial Remission Per the International Working Group (IWG) Criteria for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) — 30; 25; 10…
Phase 2 N=26 Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Systemic Mastocytosis, Aggressive (ASM) · Leukemia, Mast Cell · Hematological Non-mast Cell Lineage Disease (AHNMD)
Primary: Subjects With Clinical Response [Partial Response (PR) + Complete Response (CR)] — 25 participants
Phase 2 N=3,901 A Stage-Based Expert System for Teen Dating Violence Prevention
Violence · Bullying
Primary: Number of Participants Perpetrating Physical Dating Violence During Follow-up — 240; 307 participants — p=<.0001
Phase 2 N=18 A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection
Graft Rejection
Primary: Change From Baseline in Histopathology Endpoints — -45.0; -36.1; -6.0; 12.6 scores on a scale — p=0.6498
Phase 2 N=64 Roflumilast Plus Montelukast in Adults With Severe Asthma
Asthma
Primary: Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) — 0.18; 0.08 liters — p=0.013
Phase 2 N=46 Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
Ovarian Cancer
Primary: Progression Free Survival (PFS) by RECIST Criteria — 7.8 Months
Phase 2 N=76 Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules
Dupuytren's Disease
Primary: Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Caliper Measurements — -81.61; -80.11; -58.30; -41.76 percentage of change…
Phase 2 N=92 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: The Rate of Complete Remission (CR+CRi) — 0.143; 0.278; 0.15 proportion of participants